Business
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
WHIPPANY, N.J., December 03, 2025--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reductio
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/67c80c951f03322e376c9e58dacd0adb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iy282V.0PaCwQmEneoZjjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/67c80c951f03322e376c9e58dacd0adb","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent","length":140,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"QUANTI Pediatric evaluated the pharmacokinetics and safety of gadoquatrane in children (birth to <18) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight","length":271,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data are part of submissions to health authorities worldwide to secure marketing authorization for gadoquatrane","length":111,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":522,"olType":false},{"type":"text","content":"WHIPPANY, N.J., December 03, 2025--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. Similar pharmacokinetic behavior was observed in the pediatric population, indicating that diagnostic performance of gadoquatrane in adults can also be applied to children. Details of QUANTI Pediatric were presented as late-breaking clinical trial data at this year’s annual congress of the Radiological Society of North America (RSNA) taking place in Chicago, USA, from November 30 to December 4, 2025.","length...